Alpha 2.0
Login Register
» Authors » N Rotmensz

N Rotmensz

Explore the profile of N Rotmensz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 99
Citations 2156
Followers 0
Related Specialties
Oncology
General Surgery
General Medicine
Top 10 Co-Authors
A Goldhirsch
P Veronesi
A Luini
G Viale
E Botteri
M Intra
M Colleoni
P Maisonneuve
V Galimberti
U Veronesi
Published In
Ann Oncol
Eur J Cancer Clin Oncol
Breast Cancer Res Treat
Eur J Cancer
Eur J Surg Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery
Botteri E, Veronesi P, Vila J, Rotmensz N, Galimberti V, Thomazini M, et al.
Br J Surg . 2017 Aug; 104(13):1802-1810. PMID: 28791694
Background: The aim of the present study was to evaluate how breast cancer prognosis has evolved over time in young women treated with breast-conserving surgery (BCS). Methods: Data from patients...
2.
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast
Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio G, Rotmensz N, DeCensi A, et al.
Ann Oncol . 2017 Apr; 28(2):321-328. PMID: 28426105
Background: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic adjunct in invasive breast cancer, but their clinical role in ductal carcinoma in situ (DCIS) has not been ascertained. Patients And Methods:...
3.
Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment
Galimberti V, Ribeiro Fontana S, Maisonneuve P, Steccanella F, Vento A, Intra M, et al.
Eur J Surg Oncol . 2016 Jan; 42(3):361-8. PMID: 26746091
Purpose: It is controversial whether sentinel node biopsy (SNB) without axillary dissection (AD) should be performed in cN1/2 breast cancer patients who become cN0 after neoadjuvant treatment, since the false...
4.
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, et al.
Ann Oncol . 2015 Nov; 27(2):249-56. PMID: 26598540
Background: Although tumor-infiltrating lymphocytes (TILs) have been associated with a favorable prognosis in triple-negative breast cancer (TNBC) patients, this marker is not currently considered robust enough for entering the clinical...
5.
Oncological results of oncoplastic breast-conserving surgery: Long term follow-up of a large series at a single institution: A matched-cohort analysis
De Lorenzi F, Hubner G, Rotmensz N, Bagnardi V, Loschi P, Maisonneuve P, et al.
Eur J Surg Oncol . 2015 Sep; 42(1):71-7. PMID: 26382101
Purpose: Oncoplastic surgery is a well-established discipline that combines conserving treatment for breast cancer with immediate plastic reconstruction. Although widely practiced, the oncologic outcomes of this combined approach are reported...
6.
Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression
Fraga-Guedes C, Andre S, Mastropasqua M, Botteri E, Toesca A, Rocha R, et al.
Breast Cancer Res Treat . 2015 Apr; 151(1):131-40. PMID: 25893585
MYC amplification has been reported as a prominent feature of secondary angiosarcomas (SAS). The differential diagnosis between atypical vascular lesion (AVL) and low-grade angiosarcoma (AS) can be occasionally very difficult...
7.
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ
Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, et al.
Ann Oncol . 2015 Jan; 26(4):682-687. PMID: 25600567
Background: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexpression in patients with ductal carcinoma in situ (DCIS). Patients And Methods: We identified patients with...
8.
Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology
Intra M, Viale G, Vila J, Grana C, Toesca A, Gentilini O, et al.
Ann Surg Oncol . 2014 Dec; 22(7):2372-7. PMID: 25515197
Purpose: This retrospective study aimed to determine the feasibility, accuracy, and recurrence rates of lymphoscintigraphy and the new sentinel lymph node biopsy (SLNB) for patients with ipsilateral breast tumor recurrences...
9.
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, et al.
Ann Oncol . 2014 Nov; 26(2):307-13. PMID: 25411418
Background: Limited data are available on the prognostic value of changes in the biological features of residual tumours following neoadjuvant therapies in breast cancer patients. Patients And Methods: We collected...
10.
Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease
Galimberti V, Manika A, Maisonneuve P, Corso G, Salazar Moltrasio L, Intra M, et al.
Eur J Surg Oncol . 2014 Sep; 40(10):1203-8. PMID: 25186914
Aim: It is established that axillary dissection (AD) can be safely avoided in breast cancer patients with a negative sentinel node (SN). In the present study we assessed whether the...